/ /

ModernMedicine Resource Center More Topics


Comprehensive care program does not cut COPD hospitalizations

A trial program of patient education/planning aimed at treating exacerbations of COPD early and reducing hospitalization rates proved ineffective.

COPD Pharmacy Resource Center

A Triple Hitter in One Blast: COPD Lessons from TRILOGYPatients with severe COPD are likely to suffer frequent disease exacerbations and a reduced quality of life.
QD Fluticasone-Vilanterol combo reduces COPD exacerbationsIn patients with COPD who have a history of exacerbations, a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with fewer exacerbations than usual care without a greater risk of serious adverse events
Efficacy and safety of LABA/LAMA combinations in COPD: A network meta-analysisUpdate: LABA/LAMA combo therapies
The GOLD guidelines and COPD treatmentThe results of a study indicated that only 36% of COPD patients were prescribed treatment according to the GOLD guidelines. The patients that were on GOLD-recommended pharmacological therapy had a moderate improvement in symptoms and health resource utilization.
COPD and pharmacotherapy for smoking cessation at the VA: StudyUse of tobacco-cessation therapy was low. The study found several negative factors — and two positive predictors.
Umeclidinium triple therapy for patients with COPD: Two studiesBoth studies demonstrated statistical improvements in trough FEV1 at day 85.
Hospital discharge service by pharmacists cuts COPD readmission ratesPatients hospitalized for chronic obstructive pulmonary disease (COPD) are at high risk for 30- and 60-day readmissions. In 2008, the mean 60-day admission rate following an emergency department visit of COPD patients was 18% and the mean readmission rate was more than 30%.
Individuals with a large waist circumference may face a higher risk of developing chronic obstructive pulmonary disease (COPD), according to a study published July 7 in CMAJ (Canadian Medical Association Journal).
Increased cardiac risks in COPD with new Rx inhalersOlder patients with chronic obstructive pulmonary disease may be at increased risk for cardiovascular events with newly prescribed long-acting beta-agonists and long-acting anticholinergics.